FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 11/2024”.
The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of November 2024 we identified the following current VC trends in Europe:
- Total Healthcare & Life Sciences funding reached EUR 8,188m
- Biotech/Pharma received 60% of the total investment volume (EUR 4,893m) with oncology being the leading indication (48%)
- In November, Alentis Therapeutics (Switzerland) secured the highest transaction volume with EUR 168m, followed by Adcendo (Denmark) with EUR 126m and Cradle (Netherlands) with EUR 68m
- General Atlantic (United States) is the most active investor (by deal volume in 2024), followed by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To access the full report, please click here.